Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
$30.87
$30.75
$16.36
$30.91
$497.25M0.7390,796 shsN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$3.71
+0.5%
$4.23
$2.45
$5.55
$387.32M1.34626,520 shs340,199 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.49
+5.5%
$2.66
$2.16
$4.65
$311.50M1.277,504 shs30,020 shs
Zevia PBC stock logo
ZVIA
Zevia PBC
$0.80
-2.1%
$1.22
$0.78
$4.80
$57.62M0.56154,625 shs277,304 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
0.00%0.00%0.00%0.00%0.00%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-1.34%-4.90%-14.98%-26.64%-20.47%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-1.67%+0.85%-9.58%-21.07%-3.28%
Zevia PBC stock logo
ZVIA
Zevia PBC
-0.52%-13.99%-17.24%-47.57%-75.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/AN/AN/AN/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
1.8786 of 5 stars
3.52.00.00.01.12.50.6
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
1.6497 of 5 stars
3.03.00.00.00.64.20.0
Zevia PBC stock logo
ZVIA
Zevia PBC
2.1372 of 5 stars
3.23.00.00.00.62.51.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3.00
Buy$8.67133.60% Upside
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
2.00
Hold$6.00140.96% Upside
Zevia PBC stock logo
ZVIA
Zevia PBC
2.33
Hold$4.17419.53% Upside

Current Analyst Ratings

Latest ITMR, ZVIA, NAUT, MXCT, and DRW3 Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00
3/13/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/5/2024
MaxCyte, Inc. stock logo
MXCT
MaxCyte
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/28/2024
Zevia PBC stock logo
ZVIA
Zevia PBC
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $2.00
2/21/2024
Zevia PBC stock logo
ZVIA
Zevia PBC
Telsey Advisory Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$4.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
$41.03M12.12N/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$41.29M9.38N/AN/A$2.23 per share1.66
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/A$2.12 per shareN/A
Zevia PBC stock logo
ZVIA
Zevia PBC
$166.42M0.35N/AN/A$0.86 per share0.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/A-$1.35N/AN/AN/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$37.92M-$0.37N/AN/AN/A-91.85%-15.90%-13.94%5/7/2024 (Confirmed)
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$63.67M-$0.52N/AN/AN/AN/A-22.42%-19.58%4/30/2024 (Confirmed)
Zevia PBC stock logo
ZVIA
Zevia PBC
-$21.49M-$0.42N/AN/AN/A-12.91%-29.55%-19.72%5/8/2024 (Confirmed)

Latest ITMR, ZVIA, NAUT, MXCT, and DRW3 Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Zevia PBC stock logo
ZVIA
Zevia PBC
-$0.10N/A+$0.10N/AN/AN/A  
5/7/2024N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.14N/A+$0.14N/AN/AN/A  
4/30/2024N/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.16N/A+$0.16N/AN/AN/A  
3/12/2024Q4 2023
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.10-$0.05+$0.05-$0.05$15.60 million$15.67 million
2/28/2024Q4 2023
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.16-$0.14+$0.02-$0.14N/AN/A      
2/27/202412/31/2023
Zevia PBC stock logo
ZVIA
Zevia PBC
-$0.13-$0.14-$0.01-$0.14$37.75 million$37.79 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/AN/A
Zevia PBC stock logo
ZVIA
Zevia PBC
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
10.65
9.97
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/A
19.39
19.39
Zevia PBC stock logo
ZVIA
Zevia PBC
N/A
2.98
1.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
42.19%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
50.71%
Zevia PBC stock logo
ZVIA
Zevia PBC
53.21%

Insider Ownership

CompanyInsider Ownership
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
6.00%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
42.50%
Zevia PBC stock logo
ZVIA
Zevia PBC
11.73%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Itamar Medical Ltd. stock logo
ITMR
Itamar Medical
25716.11 millionN/ANot Optionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
143104.40 million98.13 millionOptionable
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
167125.10 million71.93 millionOptionable
Zevia PBC stock logo
ZVIA
Zevia PBC
11571.85 million63.42 millionOptionable

ITMR, ZVIA, NAUT, MXCT, and DRW3 Headlines

SourceHeadline
Zevia PBC (ZVIA) Stock Price, News, Quote & History - Yahoo FinanceZevia PBC (ZVIA) Stock Price, News, Quote & History - Yahoo Finance
finance.yahoo.com - April 24 at 11:27 PM
Zevia to Announce First Quarter 2024 Results on Wednesday, May 8, 2024Zevia to Announce First Quarter 2024 Results on Wednesday, May 8, 2024
businesswire.com - April 24 at 8:00 AM
Zevia PBC (NYSE:ZVIA) Given Average Rating of "Hold" by AnalystsZevia PBC (NYSE:ZVIA) Given Average Rating of "Hold" by Analysts
americanbankingnews.com - April 16 at 2:16 AM
Wells Fargo Keeps Their Hold Rating on Zevia PBC (ZVIA)Wells Fargo Keeps Their Hold Rating on Zevia PBC (ZVIA)
markets.businessinsider.com - April 11 at 10:43 AM
Beverages and Alcohol Stocks Q4 Recap: Benchmarking Zevia PBC (NYSE:ZVIA)Beverages and Alcohol Stocks Q4 Recap: Benchmarking Zevia PBC (NYSE:ZVIA)
finance.yahoo.com - April 9 at 10:28 AM
Zevia PBC (NYSE:ZVIA) CEO Amy Taylor Sells 30,703 SharesZevia PBC (NYSE:ZVIA) CEO Amy Taylor Sells 30,703 Shares
insidertrades.com - March 29 at 8:56 AM
Zevia PBC (NYSE:ZVIA) CEO Sells $31,317.06 in StockZevia PBC (NYSE:ZVIA) CEO Sells $31,317.06 in Stock
marketbeat.com - March 28 at 7:55 PM
Zevia PBC director sells $34.6k in company stockZevia PBC director sells $34.6k in company stock
investing.com - March 17 at 8:00 AM
Zevia PBC (NYSE:ZVIA) Director Padraic L. Spence Sells 26,199 SharesZevia PBC (NYSE:ZVIA) Director Padraic L. Spence Sells 26,199 Shares
insidertrades.com - March 16 at 10:59 AM
Zevia PBC (NYSE:ZVIA) Q4 2023 Earnings Call TranscriptZevia PBC (NYSE:ZVIA) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 28 at 9:36 AM
Q4 2023 Zevia PBC Earnings CallQ4 2023 Zevia PBC Earnings Call
finance.yahoo.com - February 27 at 11:01 PM
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Zevia PBC (ZVIA) and Celsius Holdings (CELH)Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Zevia PBC (ZVIA) and Celsius Holdings (CELH)
markets.businessinsider.com - February 27 at 1:00 PM
Zevia PBCs (NYSE:ZVIA) Q4 Sales Top Estimates ButZevia PBC's (NYSE:ZVIA) Q4 Sales Top Estimates But
finance.yahoo.com - February 27 at 1:00 PM
Zevia PBC GAAP EPS of -$0.14 in-line, revenue of $37.8M beats by $0.45MZevia PBC GAAP EPS of -$0.14 in-line, revenue of $37.8M beats by $0.45M
msn.com - February 27 at 7:59 AM
Zevia Announces Fourth Quarter and Full Year 2023 ResultsZevia Announces Fourth Quarter and Full Year 2023 Results
finance.yahoo.com - February 27 at 7:59 AM
Zevia Announces Fourth Quarter and Full Year 2023 ResultsZevia Announces Fourth Quarter and Full Year 2023 Results
businesswire.com - February 27 at 7:00 AM
Zevia Appoints Girish Satya as Chief Financial OfficerZevia Appoints Girish Satya as Chief Financial Officer
finance.yahoo.com - February 20 at 10:47 AM
Zevia Appoints Girish Satya as Chief Financial OfficerZevia Appoints Girish Satya as Chief Financial Officer
businesswire.com - February 20 at 7:00 AM
Zevia to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024Zevia to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024
finance.yahoo.com - February 13 at 12:48 PM
Jones Soda eyes Canada expansion with Mary Jones cannabis sodas and ediblesJones Soda eyes Canada expansion with Mary Jones cannabis sodas and edibles
msn.com - February 6 at 9:47 AM
Q3 Earnings Roundup: Boston Beer (NYSE:SAM) And The Rest Of The Beverages and Alcohol SegmentQ3 Earnings Roundup: Boston Beer (NYSE:SAM) And The Rest Of The Beverages and Alcohol Segment
finance.yahoo.com - January 26 at 5:42 PM
Zevia to Participate in the 26th Annual ICR ConferenceZevia to Participate in the 26th Annual ICR Conference
finance.yahoo.com - December 27 at 8:49 AM
Zevia PBC (NYSE:ZVIA) is favoured by institutional owners who hold 71% of the companyZevia PBC (NYSE:ZVIA) is favoured by institutional owners who hold 71% of the company
finance.yahoo.com - December 14 at 12:51 PM
Zevia PBC Class A ZVIAZevia PBC Class A ZVIA
morningstar.com - November 25 at 3:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Itamar Medical logo

Itamar Medical

NASDAQ:ITMR
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.
MaxCyte logo

MaxCyte

NASDAQ:MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Nautilus Biotechnology logo

Nautilus Biotechnology

NASDAQ:NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Zevia PBC logo

Zevia PBC

NYSE:ZVIA
Zevia PBC, a beverage company, develops, markets, sells, and distributes various carbonated beverages in the United States and Canada. It offers soda, energy drinks, organic tea, and kidz drinks. The company offers its products through a network of food, drug, warehouse club, mass, natural, convenience, and e-commerce channels, as well as grocery distributors and natural product stores and specialty outlets. It provides its products under the Zevia brand name. The company was founded in 2007 and is headquartered in Encino, California.